← BIOCRYST PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($55.1m) |
($65.8m)
-19.29%
|
($101.3m)
-53.92%
|
($108.9m)
-7.55%
|
($182.8m)
-67.88%
|
($184.1m)
-0.68%
|
($247.1m)
-34.26%
|
($226.5m)
+8.33%
|
($88.9m)
+60.77%
|
$263.9m
+396.87%
|
— | |
| Depreciation, Depletion and Amortization | $483k | $704k | $770k | $724k | $748k | $777k | $1.4m | $1.7m | $1.2m | $1.4m | $1.7m | |
| Amortization of Debt Issuance Costs | $558k | $876k | $885k | $1.3m | $2.4m | — | — | — | — | $1.4m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | ($682k) | ($354k) | ($1.2m) | — | |
| Share-based Payment Arrangement, Noncash Expense | $8.5m | $12.6m | $9.4m | $17.7m | $14.8m | $34.6m | $44.7m | $55.6m | $65.4m | $85.1m | $73.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | — | $2.2m | $7.5m | $8.8m | — | |
| Share-based Payment Arrangement, Expense | $8.5m | $12.6m | $9.4m | $17.7m | $14.8m | $34.6m | $44.7m | $55.6m | $65.4m | $85.1m | $73.1m | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | — | — | — | — | $85.1m | $73.1m | |
| Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | ($84.4m) | ($73.6m) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Inventories | ($1.1m) | ($500k) | $1.6m | ($1.6m) | $7.0m | $8.8m | $12.4m | $1.4m | $4.2m | $1.6m | ($11.4m) | |
| Inventory Write-down | — | — | — | — | — | — | $932k | $422k | $1.4m | $985k | — | |
| Increase (Decrease) in Accounts Payable | ($10.5m) | $3.8m | $4.5m | $11.7m | $17.4m | $39.4m | ($22.4m) | ($16.8m) | ($62.4m) | $57.8m | $57.8m | |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | — | — | — | — | — | $550k | — | |
| Net Cash Provided by (Used in) Operating Activities | ($53.4m) |
($41.1m)
+23.01%
|
($92.6m)
-124.98%
|
($89.6m)
+3.22%
|
($137.2m)
-53.17%
|
($142.2m)
-3.60%
|
($161.8m)
-13.85%
|
($95.1m)
+41.22%
|
($52.0m)
+45.32%
|
$347.4m
+767.76%
|
$376.1m
+8.28%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $5.3m | $328k | $366k | $343k | $514k | $2.4m | $1.4m | $2.2m | $1.1m | $2.5m | ($2.8m) | |
| Net Cash Provided by (Used in) Investing Activities | $23.3m | ($66.4m) | $4.8m | $77.9m | ($6.9m) | $15.8m | ($128.2m) | ($131.5m) | $52.6m | ($13.7m) | ($448.7m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | — | — | — | — | — | — | — | — | $300.0m | ($232.1m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | ($2.0m) | $55.8m | $0 | ($29.0m) | $0 | ($17.3m) | — | |
| Proceeds from Issuance of Long-term Debt | — | — | — | — | — | — | — | $300.0m | $0 | $0 | $400.0m | |
| Proceeds from Issuance of Common Stock | $317k | $134.0m | $53.4m | $58.5m | $93.3m | $50.0m | $0 | $0 | $3.4m | $9.1m | $121k | |
| Net Cash Provided by (Used in) Financing Activities | $23.3m |
$135.7m
+482.32%
|
$62.5m
-53.94%
|
$99.1m
+58.55%
|
$302.7m
+205.45%
|
$359.7m
+18.82%
|
$88.0m
-75.53%
|
$32.5m
-63.10%
|
($5.8m)
-117.73%
|
($349.9m)
-5974.14%
|
$124.6m
+135.61%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | ($25.3m) | $87.4m | $158.6m | $233.4m | ($201.5m) | ($193.8m) | ($6.1m) | ($15.0m) | $142.0m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $0 | $71k | $566k | $362k | ($936k) | $91.3m | $142.0m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $317k | $1.6m | $2.9m | $1.2m | $2.4m | $15.8m | $15.0m | — | — | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | $900k | $0 | $22.1m | $30.4m | $23.7m | — | |
| Income Taxes Paid, Net | — | — | — | — | — | $118k | $3.5m | $1.4m | $1.6m | $2.8m | — | |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Disposition of Assets | ($17k) | $12k | ($7k) | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | — | — | — | — | $3.6m | — | |
| Income Tax Expense (Benefit) | — | $0 | $0 | $0 | $0 | $2.3m | $2.7m | $310k | $1.9m | $3.5m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $98.5m | $78.9m | — | |
| Operating Lease, Expense | — | — | — | $1.5m | $1.8m | $1.8m | $2.5m | $2.0m | $2.3m | $2.0m | — | |
| Payments of Financing Costs | — | — | — | — | — | — | $34k | — | — | — | — | |
| Restructuring Costs | — | — | — | — | — | — | — | — | — | $6.3m | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | $20.7m | $48.8m | $17.8m | $157.2m | $270.8m | $331.4m | $450.7m | $874.8m | — |